人参皂苷Rg3联合沙利度胺对比最佳支持治疗对晚期肝细胞癌患者生活质量及生存期影响的前瞻性研究-国际临床研究杂志-CSCIED科技核心评价数据库-手机版

人参皂苷Rg3联合沙利度胺对比最佳支持治疗对晚期肝细胞癌患者生活质量及生存期影响的前瞻性研究

Prospective study of ginsenoside Rg3 combined with thalidomide vs best supportive care in advanced hepatocellular carcinoma: impact on quality of life and survival

ES评分 0 浏览量：186 下载量：0

全文阅读下载引用收藏

DOI	10.12208/j.ijcr.20260137
刊名	国际临床研究杂志 International Journal of Clinical Research
年，卷(期)	2026, 10(3)
作者	陈超庭¹, 崔碧玉^1,2, 赖祥丽², 刘文健³, 沈永奇²,
作者单位	广西科技大学第二附属医院肿瘤科广西柳州; 柳州市柳铁中心医院肿瘤科广西柳州; 广西科技大学第二附属医院肿瘤科广西柳州; 融水县人民医院肿瘤科广西柳州;
摘要	目的探讨人参皂苷 Rg3 联合沙利度胺对拒绝规范治疗的晚期肝细胞癌（HCC）患者的临床疗效及安全性。方法采用前瞻性随机对照设计，纳入30例晚期HCC患者（BCLC C/D 期，ECOG 0-3分），随机分为治疗组（n=14，人参皂苷Rg3 20mg bid+沙利度胺100-200mg qn+最佳支持治疗）与对照组（n=16，仅最佳支持治疗）。主要终点为生活质量（EORTC QLQ-C15 量表）及总生存期（OS），次要终点为不良反应（NCI CTCAE 4.0）。结果治疗组生存时间中位数为5.5个月（95% CI: 4.3-7.8个月）；对照组生存时间中位数为5.1个月（95% CI: 3.7-7.8个月）。采用Log-rank（Mantel-Cox）检验比较两组生存分布，结果表明治疗组与对照组的生存分布无统计学显著差异（Log-rank χ²=0.563，p=0.453）。生活质量方面，治疗组QOL“一般及以上”比例达85.7%，高于对照组的43.8%（P=0.026）。两组不良反应发生率无统计学差异（P＞0.05），均以1-2级为主。结论对于拒绝规范治疗的晚期肝细胞癌患者，人参皂苷 Rg3 联合沙利度胺虽未显著延长总生存期，但可显著改善生活质量且用药安全性可控。
Abstract	Objective To evaluate the efficacy and safety of ginsenoside Rg3 combined with thalidomide in patients with advanced hepatocellular carcinoma (HCC) who refused radical treatment. Methods A prospective randomized controlled trial was conducted. Thirty advanced HCC patients (BCLC C/D stage, ECOG 0-3) were randomly assigned to receive either ginsenoside Rg3 (20 mg bid) + thalidomide (100-200 mg qn) + best supportive care (BSC) (treatment group, n=14) or BSC alone (control group, n=16). Primary endpoints included quality of life (QOL, EORTC QLQ-C15 scale) and overall survival (OS). Secondary endpoints were adverse events (NCI CTCAE 4.0). Results Median OS was 5.5 months (95%CI:4.3–7.8) in the treatment group vs 5.1 months (95%CI:3.7–7.8) in the control group (Log-rank χ²=0.563, p=0.453). QOL improvement (≥"fair") was significantly higher in the treatment group (85.7% vs 43.8%, p=0.026). Adverse events were comparable between groups (all grade 1-2, p>0.05). Conclusion Ginsenoside Rg3 combined with thalidomide does not significantly prolong OS but improves QOL with manageable toxicity in advanced HCC patients refusing radical treatment.
关键词	人参皂苷Rg3；沙利度胺；生活质量；生存期
KeyWord	Ginsenoside Rg3; Thalidomide; Quality of life; Survival time
基金项目
页码	85-89

参考文献
相关文献

[1] Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018. 391(10127): 1301-1314.

[2] 郑淇予. 人参皂苷Rg3脂质体的制备及其抗肝癌活性与机制研究
[D] ,2022.

[3] Rafiee P, Stein DJ, Nelson VM, Otterson MF, Shaker R, Binion DG. Thalidomide inhibits inflammatory and angiogenic activation of human intestinal microvascular endothelial cells (HIMEC). Am J Physiol Gastrointest Liver Physiol. 2010. 298(2): G167-76.

[4] Chen YY, Yen HH, Chou KC, Wu SS. Thalidomide-based multidisciplinary treatment for patients with advanced hepatocellular carcinoma: a retrospective analysis. World J Gastroenterol. 2012. 18(5): 466-71.

[5] Chiou HE, Wang TE, Wang YY, Liu HW. Efficacy and safety of thalidomide in patients with hepatocellular carcinoma. World J Gastroenterol. 2006. 12(43): 6955-60.

[6] Cao DD, Xu HL, Liu L, et al. Thalidomide combined with transcatheter artierial chemoembolzation for primary hepatocellular carcinoma: a systematic review and meta-analysis. Oncotarget. 2017. 8(27): 44976-44993.

[7] 刘淮东, 朱子元, 杨飞. 沙利度胺联合化疗治疗晚期胃癌的临床观察. 中华肿瘤防治杂志. 2010. 17(21): 1768-1770.

[8] Xu TM, Xin Y, Cui MH, Jiang X, Gu LP. Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer. Chin Med J (Engl). 2007. 120(7): 584-8.

[9] 李军霞, 孙萍, 孙等军, 董亮亮, 夏玉军. 沙利度胺对人肝癌细胞株SMMC-7721荷瘤鼠移植瘤作用. 齐鲁医学杂志. 2011. 26(05): 402-404.

[10] 袁佳蕾, 陈钦开. 人参皂甙Rg3抗肿瘤机制的研究进展. 南昌大学学报(医学版). 2019. 59(05): 96-98.

[11] 丛琳, 肖静, 张文娟等. 多发性骨髓瘤患者血清VEGF和TNF-α及IL-6表达与沙利度胺联合化疗相关性研究. 中华肿瘤防治杂志. 2012. 19(05): 375-377.

[12] 庄伟霞, 陈莉, 王谋锋, 江丽, 余慧玲. 沙利度胺抗肿瘤机制基础研究分析. 中国现代药物应用. 2022. 16(15): 53-57.

[13] Kim JH, Bae YC, Lee JW, Choi JS, Bae SH. Effects of ginsenoside Rg3 on apoptosis in A375.S2 melanoma cells. Transl Cancer Res. 2019. 8(2): 357-366.

[14] Liang L, Gan M, Miao H, et al. Thalidomide attenuates radiation-induced apoptosis and pro-inflammatory cytokine secretion in oral epithelial cells by promoting LZTS3 expression. J Transl Med. 2024. 22(1): 863.

[15] 孙媛, 李青山. FOLFOX方案联合沙利度胺体外抑制人肝癌HepG2细胞VEGF、Caspase-3基因表达的研究. 中国煤炭工业医学杂志. 2015. 18(02): 289-292.

引用本文

陈超庭, 崔碧玉^,, 赖祥丽, 刘文健, 沈永奇. 人参皂苷Rg3联合沙利度胺对比最佳支持治疗对晚期肝细胞癌患者生活质量及生存期影响的前瞻性研究 [J]. 国际临床研究杂志. 2026; 10; (3). 85 - 89.

文献评论

相关学者

相关机构